Emerald Health Therapeutics’ Pure Sunfarms JV Records Q3 Net Sales of $24.0 Million, 69% Gross Margin, 56% EBITDA Margin, Fourth Consecutive Quarter of Positive EBITDA, and $0.63/gram All-in Production Cost

Emerald Health Therapeutics’ Pure Sunfarms JV Records Q3 Net Sales of .0 Million, 69% Gross Margin, 56% EBITDA Margin, Fourth Consecutive Quarter of Positive EBITDA, and {$title}.63/gram All-in Production Cost

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) has provided preliminary, unaudited financial results for the third quarter of 2019 for its BC-based, 50%-owned joint venture, Pure Sunfarms (“PSF”). The Company will report complete financial results for the third quarter ended September 30, 2019, after market close on Friday, November 29, 2019, and host its third quarter 2019 financial results conference call on Monday, December 2, 2019 at 10:30 a.m. ET. Sales for the third quarter consisted entirely of dried flower sold primarily to other licensed producers. READ MORE: https://finance.yahoo.com/news/emerald-health-therapeutics-pure-sunfarms-120000714.html?.tsrc=rss The post Emerald Health Therapeutics’ Pure Sunfarms JV Records Q3 Net Sales of $24.0 Million, 69% Gross Margin, 56% EBITDA Margin, Fourth Consecutive Quarter of Positive EBITDA, and $0.63/gram All-in Production Cost appeared first on Cannabis Daily.

Excerpt only …
READ MORE BELOW
Source : New feed
Link to original : Emerald Health Therapeutics’ Pure Sunfarms JV Records Q3 Net Sales of .0 Million, 69% Gross Margin, 56% EBITDA Margin, Fourth Consecutive Quarter of Positive EBITDA, and {$permalink}.63/gram All-in Production Cost
reposted by Cannabis News World

This site uses Akismet to reduce spam. Learn how your comment data is processed.